Background: Glycated hemoglobin (HbA1c) is a critical indicator of glycemic control in Type 2 Diabetes Mellitus (T2DM). Serum uric acid (SUA), traditionally a marker of gout, is increasingly recognized for its role in metabolic dysfunction. The interplay between SUA and glycemic control remains complex. Objective: To evaluate the association between serum uric acid levels and HbA1c among patients with T2DM. Methods: A cross-sectional study of 100 T2DM patients was conducted over 18 months. Patients were categorized by glycemic control based on HbA1c levels: good (<7%), fair (8–9%), and poor (>9%). SUA was measured using the uricase enzymatic method and compared across these categories. Results: Mean SUA levels were highest in patients with HbA1c <7% (6.2 ± 1.1 mg/dL), lower in those with HbA1c 8–9% (5.4 ± 0.9 mg/dL), and lowest in those with HbA1c >9% (4.1 ± 0.7 mg/dL). There was a statistically significant inverse correlation (r = -0.42, p < 0.01) between SUA and HbA1c. Conclusion: SUA levels decline with worsening glycemic control in T2DM, suggesting that elevated SUA may be more prominent in early or well-controlled diabetes. These findings highlight SUA's potential as a marker for insulin resistance rather than advanced hyperglycemia.